Beta-2 Glycoprotein 1 Antibodies, IgG, Serum
Use
The test is used for evaluating patients with suspected antiphospholipid syndrome by identifying beta-2 glycoprotein 1 IgG antibodies. It is a first-line test when antiphospholipid syndrome is strongly suspected, especially in conjunction with cardiolipin antibodies (IgG and IgM) and lupus anticoagulant testing. The test is significant for estimating the risk of thrombosis and/or pregnancy-related morbidity in patients with systemic lupus erythematosus.
Special Instructions
Not provided.
Limitations
Immunoassays for detecting antiphospholipid antibodies, including beta-2 glycoprotein 1, may not fully distinguish between autoantibodies specific for antiphospholipid syndrome and antibodies produced in response to infectious agents. The presence of antibodies needs to be persistent across 2 or more occasions, at least 12 weeks apart, for a definitive diagnosis. Additionally, different commercial immunoassays may yield variable results, necessitating standardized assay practices.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
Beta-2 Glycoprotein 1
Protein
LOINC Codes
- 44448-9 - B2 Glycoprot1 IgG SerPl IA-aCnc
- 44448-9 - B2 Glycoprot1 IgG SerPl IA-aCnc
Result Turnaround Time
2-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Serum gel (preferred) or red top
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |